Most Clicked StoriesMore >


Gilead CEO expresses regret over pricing of Sovaldi

PCMA SmartBrief | Dec 08, 2016

Gilead Sciences CEO John Milligan said the company did not anticipate the surge in patients who would be treated for hepatitis C after the introduction of Sovaldi and the impact on payers because of the drug's high price. "I think our failure, if I have to take a step backwards, we were unable to have a good enough conversation with the payers," Milligan said. Forbes (12/08)


Mylan CEO takes full responsibility for EpiPen price hikes

PCMA SmartBrief | Dec 02, 2016

Pharma CEOs divided on large price increases

PCMA SmartBrief | Dec 02, 2016

HHS nominee wants to reduce government's role in health care

PCMA SmartBrief | Dec 05, 2016

Drug-plan sponsors have plenty of PBM choices

PCMA SmartBrief | Dec 08, 2016

Pence says no to overhauling Medicare, SS; yes to Medicaid changes

PCMA SmartBrief | Dec 06, 2016

PBM-negotiated discounts reducing global growth in drug spending

PCMA SmartBrief | Dec 06, 2016

Side effects of cancer immunotherapy threaten vital organs in some

PCMA SmartBrief | Dec 05, 2016

Copay coupons deflect attention from price hikes

PCMA SmartBrief | Dec 08, 2016

PBMs hold down drug prices, more competition important in Rx marketplace

PCMA SmartBrief | Dec 07, 2016


Find PCMA SmartBrief Issues by Date:





Sign up for PCMA SmartBrief



Designed specifically for PBM industry professionals, PCMA SmartBrief is a FREE, daily e-mail newsletter. It provides the the most relevant and actionable PBM industry news in a quick, easy to read format. Learn more